☰

Toni M. Brand, Ph.D. - Publications

Affiliations: 
2014 Cellular & Molecular Pathology University of Wisconsin, Madison, Madison, WI 
Area:
Cell Biology, Oncology, Pharmacology
Tree Info Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Retraction. Science Signaling. 14: eabn0168. PMID 34752142 DOI: 10.1126/scisignal.abn0168  0.468
2019 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868. PMID 30936412 DOI: 10.1158/1535-7163.MCT-18-1183  0.638
2018 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. PMID 30518873 DOI: 10.1038/S41388-018-0572-X  0.592
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.Ccr-18-3194  0.571
2018 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77]. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 30442378 DOI: 10.1016/J.Radonc.2018.10.011  0.695
2018 Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. PMID 30390071 DOI: 10.1038/S41388-018-0537-0  0.419
2018 Leonard B, Brand TM, O'Keefe RA, Lee E, Zang Y, Kemmer JD, Li H, Grandis JR, Bhola NE. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research. PMID 29792310 DOI: 10.1158/0008-5472.Can-18-0459  0.463
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10. PMID 28049763 DOI: 10.1126/Scisignal.Aag1064  0.77
2017 Brand T, Zeng Y, Leonard B, Keefe RO, Li H, Johnson D, Grandis J, Bhola NE. Abstract 95: Targeting BRD4 overcomes cetuximab resistance in HNSCC Cancer Research. 77: 95-95. DOI: 10.1158/1538-7445.Am2017-95  0.395
2017 Black NK, Iida M, Rodems TS, Brand TM, Kimple RJ, Wheeler DL. Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC Cancer Research. 77: 4176-4176. DOI: 10.1158/1538-7445.Am2017-4176  0.724
2017 O'Keefe RA, Bhola N, Brand TM, Zeng Y, Johnson DE, Grandis JR. Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma Cancer Research. 77: 4108-4108. DOI: 10.1158/1538-7445.Am2017-4108  0.344
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor Cancer Research. 77: 3333-3333. DOI: 10.1158/1538-7445.Am2017-3333  0.671
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  0.751
2016 Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Adaptive responses to antibody based therapy. Seminars in Cell & Developmental Biology. 50: 153-63. PMID 26808665 DOI: 10.1016/J.Semcdb.2016.01.001  0.725
2016 Flanigan BG, Iida M, Brand TM, Wheeler DL. Abstract 247: Understanding the role of tyrosine 1101 in the nuclear translocation of the epidermal growth factor receptor Cancer Research. 76: 247-247. DOI: 10.1158/1538-7445.Am2016-247  0.753
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  0.631
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.743
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  0.768
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  0.763
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  0.651
2014 Villaflor VM, Wheeler D, Iida M, Vidwans S, Turski M, Brand TM, Won B, Ferguson MK, Patti MG, Posner M, Waxman I, Gordon G, Vokes EE, Salgia R. Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for therapeutic targets. Journal of Clinical Oncology. 32: e22065-e22065. DOI: 10.1200/Jco.2014.32.15_Suppl.E22065  0.637
2014 Brand TM, Iida M, Corrigan KL, Luthar N, Hornung M, Toulany M, Gill P, Salgia R, Wheeler DL. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-215  0.773
2013 Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia (New York, N.Y.). 15: 1196-206. PMID 24204198 DOI: 10.1593/Neo.131584  0.742
2013 Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discovery Medicine. 16: 79-92. PMID 23998444  0.647
2013 Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. Plos One. 8: e71518. PMID 23951180 DOI: 10.1371/Journal.Pone.0071518  0.656
2013 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 108: 370-7. PMID 23830194 DOI: 10.1016/J.Radonc.2013.06.010  0.776
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  0.653
2013 Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy. 14: 481-91. PMID 23760490 DOI: 10.4161/Cbt.24342  0.752
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  0.675
2013 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 32: 759-67. PMID 22430206 DOI: 10.1038/Onc.2012.90  0.755
2013 Brand TM, Iida M, Luthar N, Wleklinski M, Kostopoulos K, Wheeler DL. Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-219  0.763
2013 Iida M, Brand TM, Starr MM, Luthar N, Wleklinski MJ, Wheeler DL. Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy. Cancer Research. 73: 5646-5646. DOI: 10.1158/1538-7445.Am2013-5646  0.762
2013 Brand TM, Iida M, Wleklinski MJ, Luthar N, Starr MM, Wheeler DL. Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases. Cancer Research. 73: 4276-4276. DOI: 10.1158/1538-7445.Am2013-4276  0.685
2012 Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small Gtpases. 3: 34-9. PMID 22714415 DOI: 10.4161/Sgtp.18751  0.714
2012 Li C, Iida M, Huang S, Armstrong EA, Brand TM, Peet CR, Wheeler DL. Abstract 5726: Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas Cancer Research. 72: 5726-5726. DOI: 10.1158/1538-7445.Am2012-5726  0.691
2011 Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine. 12: 419-32. PMID 22127113  0.726
2011 Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology & Therapy. 12: 436-46. PMID 21725209 DOI: 10.4161/Cbt.12.5.16394  0.759
2011 Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy. 11: 777-92. PMID 21293176 DOI: 10.4161/Cbt.11.9.15050  0.776
2011 Brand TM, Wheeler DL. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biology & Therapy. 11: 368-70. PMID 21228636 DOI: 10.4161/Cbt.11.3.14696  0.636
2011 Brand TM, Dunn EF, Iida M, Myers R, Li C, Wheeler DL. Abstract 726: Erlotinib overcomes acquired resistance to cetuximab Cancer Research. 71: 726-726. DOI: 10.1158/1538-7445.Am2011-726  0.756
2011 Iida M, Campbell DA, Brand TM, Li C, Wheeler DL. Abstract A146: Targeting AKT signaling overcomes acquired resistance to cetuximab in non-small lung cancer cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A146  0.739
2010 Iida M, Li C, Brand T, Peet C, Wheeler D. 101 Identification of EGFR regulated genes in cetuximab resistant tumor cell models European Journal of Cancer Supplements. 8: 39. DOI: 10.1016/S1359-6349(10)71806-1  0.691
Show low-probability matches.